SCHEMBL9904404

SCHEMBL9904404

CC(C)(C)OC(=O)NC1CCN(c2cncc(-c3nn(C4CCCCO4)c4ccc(-c5cnc6[nH]nc(C(F)(F)F)c6c5)cc34)n2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 1/20 0.40
▸ SKP1 P63208 1/20 0.40
▸ SKP2 Q13309 1/20 0.40
▸ SYK P43405 2/20 0.37
▸ AURKA O14965 3/20 0.34
▸ PDPK1 O15530 3/20 0.34
▸ AURKB Q96GD4 3/20 0.34
▸ RET P07949 1/20 0.34
▸ ITGB2 P05107 1/20 0.34
▸ ICAM1 P05362 1/20 0.34
▸ ITGAL P20701 1/20 0.34
▸ ATR Q13535 4/20 0.34
▸ DYRK1A Q13627 3/20 0.34
▸ WNT1 P04628 2/20 0.34
▸ ATM Q13315 1/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ PIM3 Q86V86 1/20 0.33
▸ PIM2 Q9P1W9 1/20 0.33
▸ KDM4D Q6B0I6 1/20 0.33
▸ BTK Q06187 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904770 0.86 CKS1B (0.45) CKS1BSKP1SKP2SYKRET
SCHEMBL9904327 0.83 CKS1B (0.44) CKS1BSKP1SKP2SYKRET
SCHEMBL9904356 0.81 CKS1B (0.41) CKS1BSKP1SKP2SYKAURKA
SCHEMBL15440351 0.81 CKS1B (0.41) CKS1BSKP1SKP2RETATR
SCHEMBL9904589 0.79 PIM1 (0.45) CKS1BSKP1SKP2SYKAURKA
SCHEMBL9904479 0.79 CKS1B (0.40) CKS1BSKP1SKP2RETATR
SCHEMBL9905715 0.77 RXRA (0.39) CKS1BSKP1SKP2ATRDYRK1A
SCHEMBL9904737 0.74 WNT1 (0.39) CKS1BSKP1SKP2RETATR
SCHEMBL9904319 0.72 DYRK1A (0.42) ATRDYRK1APIM1PIM3PIM2
SCHEMBL9904708 0.72 RXRA (0.38) CKS1BSKP1SKP2ATRPIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 — — US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 — — EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 CKS1B 342/4885SKP1 176/4885SKP2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback